Cebranopadol – a dual-NMR agonist working on nociceptin/orphanin FQ peptide (NOP) and mu-opioid peptide (MOP) receptors – is a potential first-in-class alternative to opioid analgesics ...

Healthcare companies were flat as traders rotated into higher-risk sectors. Shares of Hims & Hers rallied after the online pharmacy said it would continue selling compounded versions of glucagon-like ...

While more research is needed, experts consider semaglutide a promising development in addressing alcohol addiction.

Atogepant vs placebo for the preventative treatment of migraine alleviated migraine symptoms across 3 clinical trials on day 1.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Learn more about whether Globus Medical, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor ...

DWTX READ THE FULL DWTX RESEARCH REPORT Business Update First Patient Dosed in Phase 2b Trial of Halneuron® On March 18, 2025 ...

The extension of the emergency declaration, originally set to expire on March 21, continues to allocate funding to addressing the opioid crisis. The Trump administration announced on Wednesday ...

Endo's slide into bankruptcy follows in the footsteps of Purdue Pharma – which filed in 2019 but is still negotiating opioid settlement and corporate restructuring terms – as well as ...

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating ...